查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
北美生物製药市场预测至 2028 年 - 区域分析 - 按产品类型和应用
市场调查报告书
商品编码
1360047

北美生物製药市场预测至 2028 年 - 区域分析 - 按产品类型和应用

North America Biopharmaceuticals Market Forecast to 2028 -Regional Analysis - by Product Type and Application
出版日期: | 出版商: The Insight Partners | 英文 224 Pages | 订单完成后即时交付

价格

2022年北美生物製药市场估值为1,512.2亿美元，预计到2028年将达到3,157.4亿美元。预计2022年至2028年复合年增长率为13.1%。

治疗罕见疾病的潜力推动北美生物製药市场

根据美国国立卫生研究院 (NIH) 的报告，有 3,000 万美国人（占总人口的 10%）患有约 7,000 种已知罕见疾病之一。开发治疗这些罕见疾病的药物面临科学和操作上的挑战。与罕见疾病相关的复杂生物学为科学家设计和实施新药开发计画带来了挑战。然而，儘管面临这些挑战，北美的生物製药研究人员仍然开发了治疗罕见疾病的新技术并开发了突破性的疗法。此外，在过去十年中，美国 FDA 批准了 350 种孤儿药，特别是针对缺乏治疗或治疗选择有限的疾病。转甲状腺素蛋白淀粉样心肌病变 (ATTR-CM) 是一种危及生命的进行性心血管罕见疾病，其特征是心臟功能异常，导致浸润性心肌病变。一旦确诊，如果不及时治疗，中位数预期寿命仅为 2.5-3.5 年。此外，生物製药公司 Ultragenyx Pharmaceutical Inc. 致力于治疗 3 型糖原贮积症 (GSD) 这种严重罕见的超遗传性疾病的分子的安全性测试和剂量确定。该公司于2021年12月启动了UX053的临床研究，将其作为第一个治疗GSD3患者的潜在药物推出。 UX053 mRNA 可以将大基因递送至目标细胞，以实现蛋白质表现的高度一致性。该公司计划根据每位患者的需求，透过调整剂量水平和频率来个性化 mRNA 疗法。此类临床开发、上市和批准正在加速北美生物製药市场的扩张。

北美生物製药市场概况

北美生物製药市场分为美国、加拿大和墨西哥。该地区的市场成长归因于癌症发生率的增加、该地区产品引进的增加以及生物製药技术的进步。生物製药产业正处于医学研究的关键阶段，具有进一步彻底改变阿兹海默症、癌症、心臟病和丙型肝炎等昂贵且衰弱性疾病的治疗的巨大潜力。慢性病负担不断增加，研发投资不断增加美国的活动正在推动该地区的市场。生物製药产业对美国经济做出了重要贡献。美国在大多数研发投资和创新指数方面领先世界。截至2020年，美国生物製药公司有超过3,400种药物处于临床开发阶段，几乎占全球估计8,000种药物的一半（其中1,100种正在开髮用于治疗各种类型的癌症）。生物製药产业透过创造直接经济活动和支持间接经济活动，为美国经济做出了重要贡献。 2018年，製药和医疗製造业占私部门增加价值的0.95%。生技研发设施又占0.23%。美国疾病管制与预防中心 (CDC) 于 2022 年 7 月更新的数据显示，冠状动脉疾病是最常见的心臟病。在美国，大约有 2010 万 20 岁及以上的成年人患有这种疾病。根据CDC资料，每40秒就有一人心臟病发作，美国每年有近80.5万人心臟病发作。所有这些因素预计将在预测期内显着推动北美生物製药市场的成长。

北美生物製药市场收入及 2028 年预测（十亿美元）

北美生物製药市场细分

北美生物製药市场按产品类型、应用和国家细分。

根据产品类型，北美生物製药市场分为单株抗体、重组疫苗、常规疫苗、重组生长因子、纯化蛋白、重组蛋白、重组激素、重组酶、细胞和基因疗法、细胞激素/干扰素/白血球介素和其他的。 2022年，单株抗体领域占据北美生物製药市场的最大份额。

重组疫苗细分为癌症疫苗、疟疾疫苗、伊波拉疫苗、B型肝炎疫苗、破伤风疫苗、白喉疫苗、霍乱疫苗等。传统疫苗细分为小儿麻痹疫苗、痘疫苗等。重组生长因子片段进一步细分为红血球生成素和粒细胞集落刺激因子。纯化的蛋白质片段进一步细分为白血病抑制因子（LIF）、P53蛋白、P38蛋白等。重组蛋白片段进一步分为血清白蛋白、淀粉样蛋白、防御素和转铁蛋白。重组激素细分为重组人生长激素、重组胰岛素和其他重组激素。重组酶片段进一步分为肠激酶、环化酶、半胱天冬酶和组织蛋白酶。细胞和基因治疗领域进一步细分为同种异体产品、自体产品和非细胞产品。

根据应用，北美生物製药市场分为肿瘤学、发炎和传染病、自体免疫疾病、代谢障碍、荷尔蒙失调和生长障碍、心血管疾病、神经系统疾病等。 2022年，肿瘤学领域占据北美生物製药市场的最大份额。

按国家/地区划分，北美生物製药市场分为美国、加拿大和墨西哥。 2022年，美国占据北美生物製药市场最大份额。

艾伯维公司、AGC Biologics AS、安进公司、勃林格殷格翰国际有限公司、百时美施贵宝公司、礼来公司、强生公司、龙沙集团、赛默飞世尔科技公司和药明生物公司是在该领域运营的领先公司。北美生物製药市场。

目录

第 1 章：简介

  • 研究范围
  • Insight Partners 研究报告指南
  • 市场区隔
    • 北美生物製药市场 - 按产品类型
    • 北美生物製药市场 - 按应用
    • 北美生物製药市场 - 按国家划分

第 2 章：北美生物製药市场 - 要点

第 3 章：研究方法

  • 覆盖范围
  • 二次研究
  • 初步研究

第 4 章：北美生物製药市场 - 市场格局

  • 概述
  • 北美 PEST 分析
  • 专家意见

第 5 章：北美生物製药市场 - 主要市场动态

  • 市场驱动因素
    • 在癌症治疗的应用不断增加
    • 治疗罕见疾病的潜力
  • 市场限制
    • 製造基础设施成本高昂
  • 市场机会
    • 加速临床试验
  • 未来的趋势
    • 生物製药合约製造
  • 影响分析

第 6 章：生物製药市场 - 北美分析

  • 北美生物製药市场收入预测与分析

第 7 章：北美生物製药市场 - 2028 年收入和预测 - 按产品类型

  • 概述
  • 2021 年和 2028 年北美生物製药市场收入份额（按产品类型划分）（%）
  • 单株抗体
  • 重组疫苗
  • 常规疫苗
  • 重组生长因子
  • 纯化蛋白质
  • 重组蛋白
  • 重组激素
  • 重组酵素
  • 细胞和基因疗法
  • 细胞激素/干扰素/白血球介素
  • 其他（基于 mRNA 的疗法等）

第 8 章：2028 年北美生物製药市场分析与预测 -按应用

  • 概述
  • 北美生物製药市场，按应用分类 2021 年和 2028 年 (%)
  • 肿瘤学
  • 发炎和传染病
  • 自体免疫疾病
  • 代谢紊乱
  • 荷尔蒙失调与生长障碍
  • 心血管疾病
  • 神经系统疾病
  • 其他治疗应用

第 9 章：北美生物製药市场 - 2028 年收入与预测 - 国家分析

    • 北美洲
      • 美国
      • 加拿大
      • 墨西哥

第 10 章：北美生物製药市场 - 产业格局

  • 概述
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第 11 章：公司简介

  • Amgen Inc
  • AbbVie Inc
  • Eli Lilly and Co
  • Bristol-Myers Squibb Co
  • Johnson & Johnson
  • Boehringer Ingelheim International GmbH
  • Thermo Fisher Scientific Inc
  • AGC Biologics AS
  • Lonza Group AG
  • WuXi Biologics Inc

第 12 章：附录

  • 关于 Insight Partners
  • 专业术语
Product Code: BMIRE00028630

The North America biopharmaceuticals market was valued at US$ 151.22 billion in 2022 and is expected to reach US$ 315.74 billion by 2028. It is estimated to register a CAGR of 13.1% from 2022 to 2028.

Potential to Treat Rare Diseases Drives North America Biopharmaceuticals Market

According to the National Institute of Health (NIH) report, 30 million Americans, accounting for 10% of the population, have one of the ~7,000 known rare diseases. Developing medicines for treating these rare diseases presents both scientific and operational challenges. Complex biology associated with rare diseases presents challenges for scientists to design and implement new drug development programs. However, despite these challenges, biopharmaceutical researchers in the North America have developed new technologies for treating rare diseases and developing groundbreaking therapies. Moreover, in the last decade, 350 orphan drugs have been approved by USFDA, particularly for conditions lacking treatment or having limited treatment options. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening, progressive cardiovascular rare disease characterized by the abnormal functioning of the heart, causing infiltrative cardiomyopathy. Once diagnosed, the median life expectancy is only ~2.5-3.5 years if left untreated. Further, biopharmaceuticals company Ultragenyx Pharmaceutical Inc. is engaged in the safety testing and dosage determination of molecules developed to treat Glycogen Storage Disease (GSD) type 3, a serious rare and ultra-genetic disease. The company initiated the clinical studies of UX053 in December 2021 to launch it as the first potential medicine for treating patients living with GSD3. The UX053 mRNA can deliver large genes to targeted cells for achieving a high uniformity of protein expression. The company plans to individualize mRNA therapies based on the needs of each patient through the adjustment of dose levels and frequency. Such clinical developments, launches, and approvals are accelerating the North America biopharmaceuticals market expansion.

North America Biopharmaceuticals Market Overview

The North America biopharmaceuticals market is segmented into the US, Canada, and Mexico. The market growth in this region is attributed to the increasing incidence of cancer, growing product introduction in the region, and technological advancements in biopharmaceuticals. The biopharmaceuticals industry is at a pivotal stage in medical research with tremendous potential to further revolutionize the treatment of costly and debilitating diseases such as Alzheimer's, cancer, heart disease, and hepatitis C. The rising burden of chronic diseases and increased investment in research and development activities in the US are driving the market in the region. The biopharmaceuticals industry makes important contributions to the US economy. The US leads the world in most R&D investment and innovation indices. As of 2020, biopharmaceutical companies in the United States have more than 3,400 drugs in clinical development, accounting for almost half of the estimated 8,000 drugs worldwide (of which 1,100 are being developed to treat various types of cancer). The biopharmaceuticals industry makes important contributions to the US economy by creating direct economic activities and supporting indirect activities. Pharmaceutical and medical manufacturing accounted for 0.95% of private sector value added in 2018. Biotech R&D facilities accounted for another 0.23%. Data from the Centers for Disease Control and Prevention (CDC), updated in July 2022, shows that coronary artery disease is the most common form of heart disease. Approximately 20.1 million adults aged 20 and older in the United States suffer from this condition. According to CDC data, someone suffers a heart attack every 40 seconds, and nearly 805,000 people in the US suffer a heart attack annually. All these factors are expected to boost the North America biopharmaceuticals market growth significantly during the forecast period.

North America Biopharmaceuticals Market Revenue and Forecast to 2028 (US$ Billion)

North America Biopharmaceuticals Market Segmentation

The North America biopharmaceuticals market is segmented into product type, application, and country.

Based on product type, the North America biopharmaceuticals market is segmented into monoclonal antibodies, recombinant vaccines, conventional vaccines, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, recombinant enzymes, cell & gene therapies, cytokines/interferon/interleukins, and others. In 2022, the monoclonal antibodies segment held the largest share of the North America biopharmaceuticals market.

The recombinant vaccines segment is further segmented into cancer vaccine, malaria vaccine, Ebola vaccine, hepatitis-B vaccine, tetanus vaccine, diphtheria vaccine, cholera vaccine, and others. The conventional vaccines segment is further segmented into polio vaccine, pox vaccine, and others. The recombinant growth factors segment is further segmented into erythropoietin and granulocyte colony stimulating factor. The purified proteins segment is further segmented into leukemia inhibitory factor (LIF), P53 protein, P38 protein, and others. The recombinant proteins segment is further segmented into serum albumin, amyloid protein, defensin, and transferrin. The recombinant hormones segment is further segmented into recombinant human growth hormones, recombinant insulin, and other recombinant hormones. The recombinant enzymes segment is further segmented into enterokinase, cyclase, caspase, and cathepsin. The cell & gene therapies segment is further segmented into allogenic products, autologous products, and acellular products.

Based on application, the North America biopharmaceuticals market is segmented into oncology, inflammatory & infectious disease, autoimmune disorders, metabolic disorders, hormonal disorders & growth failure, cardiovascular diseases, neurological diseases, and others. In 2022, the oncology segment held the largest share of the North America biopharmaceuticals market.

Based on country, the North America biopharmaceuticals market is segmented into the US, Canada, and Mexico. In 2022, the US accounted for the largest share of the North America biopharmaceuticals market.

AbbVie Inc, AGC Biologics AS, Amgen Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, Eli Lilly and Co, Johnson & Johnson, Lonza Group AG, Thermo Fisher Scientific Inc, and WuXi Biologics Inc are the leading companies operating in the North America biopharmaceuticals market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America biopharmaceutical market.
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The key findings and recommendations highlight crucial progressive industry trends in the North America biopharmaceutical market, thereby allowing players across the value chain to develop effective long-term strategies
  • develop/modify business expansion plans by using substantial growth offering developed and emerging markets
  • Scrutinize in-depth North America market trends and outlook coupled with the factors driving the biopharmaceutical market, as well as those hindering it
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 North America Biopharmaceuticals Market - by Product Type
    • 1.3.2 North America Biopharmaceuticals Market - by Application
    • 1.3.3 North America Biopharmaceuticals Market - by Country

2. North America Biopharmaceuticals Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Biopharmaceuticals Market - Market Landscape

  • 4.1 Overview
  • 4.2 North America PEST Analysis
  • 4.3 Expert's Opinion

5. North America Biopharmaceuticals Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Application in Cancer Therapeutics
    • 5.1.2 Potential to Treat Rare Diseases
  • 5.2 Market Restraints
    • 5.2.1 High Cost of Manufacturing Infrastructure
  • 5.3 Market Opportunities
    • 5.3.1 Accelerated Clinical Trials
  • 5.4 Future Trends
    • 5.4.1 Contract Manufacturing of Biopharmaceuticals
  • 5.5 Impact Analysis

6. Biopharmaceuticals Market - North America Analysis

  • 6.1 North America Biopharmaceuticals Market Revenue Forecast and Analysis

7. North America Biopharmaceuticals Market - Revenue and Forecast to 2028 - by Product Type

  • 7.1 Overview
  • 7.2 North America Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
  • 7.3 Monoclonal Antibodies
    • 7.3.1 Overview
    • 7.3.2 Monoclonal Antibodies: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.4 Recombinant Vaccines
    • 7.4.1 Overview
    • 7.4.2 Recombinant Vaccines: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.1 Cancer Vaccine
        • 7.4.2.1.1 Overview
        • 7.4.2.1.2 Cancer Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.2 Malaria Vaccine
        • 7.4.2.2.1 Overview
        • 7.4.2.2.2 Malaria Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.3 Ebola Vaccine
        • 7.4.2.3.1 Overview
        • 7.4.2.3.2 Ebola Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.4 Hepatitis-B Vaccine
        • 7.4.2.4.1 Overview
        • 7.4.2.4.2 Hepatitis-B Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.5 Tetanus Vaccine
        • 7.4.2.5.1 Overview
        • 7.4.2.5.2 Tetanus Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.6 Diphtheria Vaccine
        • 7.4.2.6.1 Overview
        • 7.4.2.6.2 Diphtheria Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.7 Cholera Vaccine
        • 7.4.2.7.1 Overview
        • 7.4.2.7.2 Cholera Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.8 Others
        • 7.4.2.8.1 Overview
        • 7.4.2.8.2 Others: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.5 Conventional Vaccines
    • 7.5.1 Overview
    • 7.5.2 Conventional Vaccines: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.5.2.1 Polio Vaccine
        • 7.5.2.1.1 Overview
        • 7.5.2.1.2 Polio Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.5.2.2 Pox Vaccine
        • 7.5.2.2.1 Overview
        • 7.5.2.2.2 Pox Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.5.2.3 Other Conventional Vaccine
        • 7.5.2.3.1 Overview
        • 7.5.2.3.2 Other Conventional Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.6 Recombinant Growth Factors
    • 7.6.1 Overview
    • 7.6.2 Recombinant Growth Factors: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.6.2.1 Erythropoietin
        • 7.6.2.1.1 Overview
        • 7.6.2.1.2 Erythropoietin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.6.2.2 Granulocyte Colony Stimulating Factor
        • 7.6.2.2.1 Overview
        • 7.6.2.2.2 Granulocyte Colony Stimulating Factor: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.7 Purified Proteins
    • 7.7.1 Overview
    • 7.7.2 Purified Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.7.2.1 Leukemia Inhibitory Factor (LIF)
        • 7.7.2.1.1 Overview
        • 7.7.2.1.2 Leukemia Inhibitory Factor (LIF): North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.7.2.2 P53 Protein
        • 7.7.2.2.1 Overview
        • 7.7.2.2.2 P53 Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.7.2.3 P38 Protein
        • 7.7.2.3.1 Overview
        • 7.7.2.3.2 P38 Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.7.2.4 Other Purified Proteins
        • 7.7.2.4.1 Overview
        • 7.7.2.4.2 Other Purified Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.8 Recombinant Proteins
    • 7.8.1 Overview
    • 7.8.2 Recombinant Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.8.2.1 Serum Albumin
        • 7.8.2.1.1 Overview
        • 7.8.2.1.2 Serum Albumin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.8.2.2 Amyloid Protein
        • 7.8.2.2.1 Overview
        • 7.8.2.2.2 Amyloid Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.8.2.3 Defensin
        • 7.8.2.3.1 Overview
        • 7.8.2.3.2 Defensin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.8.2.4 Transferrin
        • 7.8.2.4.1 Overview
        • 7.8.2.4.2 Transferrin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.9 Recombinant Hormones
    • 7.9.1 Overview
    • 7.9.2 Recombinant Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.9.2.1 Recombinant Human Growth Hormones
        • 7.9.2.1.1 Overview
        • 7.9.2.1.2 Recombinant Human Growth Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.9.2.2 Recombinant Insulin
        • 7.9.2.2.1 Overview
        • 7.9.2.2.2 Recombinant Insulin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.9.2.3 Other Recombinant Hormones
        • 7.9.2.3.1 Overview
        • 7.9.2.3.2 Other Recombinant Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.10 Recombinant Enzymes
    • 7.10.1 Overview
    • 7.10.2 Recombinant Enzymes: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.10.2.1 Enterokinase
        • 7.10.2.1.1 Overview
        • 7.10.2.1.2 Enterokinase: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.10.2.2 Cyclase
        • 7.10.2.2.1 Overview
        • 7.10.2.2.2 Cyclase: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.10.2.3 Caspase
        • 7.10.2.3.1 Overview
        • 7.10.2.3.2 Caspase: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.10.2.4 Cathepsin
        • 7.10.2.4.1 Overview
        • 7.10.2.4.2 Cathepsin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.11 Cell and Gene Therapies
    • 7.11.1 Overview
    • 7.11.2 Cell and Gene Therapies: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.11.2.1 Allogenic Products
        • 7.11.2.1.1 Overview
        • 7.11.2.1.2 Allogenic Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.11.2.2 Autologous Products
        • 7.11.2.2.1 Overview
        • 7.11.2.2.2 Autologous Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.11.2.3 Acellular Products
        • 7.11.2.3.1 Overview
        • 7.11.2.3.2 Acellular Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.12 Cytokines/Interferon/Interleukins
    • 7.12.1 Overview
    • 7.12.2 Cytokines/Interferon/Interleukins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.13 Others (mRNA Based Therapeutics, etc.)
    • 7.13.1 Overview
    • 7.13.2 Others (mRNA Based Therapeutics, etc.): North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)

8. North America Biopharmaceuticals Market Analysis and Forecasts to 2028 - by Application

  • 8.1 Overview
  • 8.2 North America Biopharmaceuticals Market, by Application 2021 & 2028 (%)
  • 8.3 Oncology
    • 8.3.1 Overview
    • 8.3.2 Oncology: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.4 Inflammatory and Infectious Diseases
    • 8.4.1 Overview
    • 8.4.2 Inflammatory and Infectious Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.5 Autoimmune Disorders
    • 8.5.1 Overview
    • 8.5.2 Autoimmune Disorders: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.6 Metabolic Disorders
    • 8.6.1 Overview
    • 8.6.2 Metabolic Disorders: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.7 Hormonal Disorders and Growth Failure
    • 8.7.1 Overview
    • 8.7.2 Hormonal Disorders and Growth Failure: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.8 Cardiovascular Diseases
    • 8.8.1 Overview
    • 8.8.2 Cardiovascular Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.9 Neurological Diseases
    • 8.9.1 Overview
    • 8.9.2 Neurological Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.10 Other Therapeutic Applications
    • 8.10.1 Overview
    • 8.10.2 Other Therapeutic Applications: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)

9. North America Biopharmaceuticals Market - Revenue and Forecast to 2028 - Country Analysis

  • 9.1 Overview
    • 9.1.1 North America: Biopharmaceuticals Market, by Country
      • 9.1.1.1 United States: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.1.1.1 United States: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
        • 9.1.1.1.1.1 United States: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.1.1.2 United States: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.1.1.3 United States: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
        • 9.1.1.1.1.4 United States: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
        • 9.1.1.1.1.5 United States: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
        • 9.1.1.1.1.6 United States: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
        • 9.1.1.1.1.7 United States: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
        • 9.1.1.1.1.8 United States: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
        • 9.1.1.1.2 United States: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
      • 9.1.1.2 Canada: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.1.2.1 Canada: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
        • 9.1.1.2.1.1 Canada: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.2.1.2 Canada: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.2.1.3 Canada: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
        • 9.1.1.2.1.4 Canada: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
        • 9.1.1.2.1.5 Canada: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
        • 9.1.1.2.1.6 Canada: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
        • 9.1.1.2.1.7 Canada: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
        • 9.1.1.2.1.8 Canada: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
        • 9.1.1.2.2 Canada: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
      • 9.1.1.3 Mexico: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.1.3.1 Mexico: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
        • 9.1.1.3.1.1 Mexico: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.3.1.2 Mexico: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.3.1.3 Mexico: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
        • 9.1.1.3.1.4 Mexico: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
        • 9.1.1.3.1.5 Mexico: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
        • 9.1.1.3.1.6 Mexico: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
        • 9.1.1.3.1.7 Mexico: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
        • 9.1.1.3.1.8 Mexico: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
        • 9.1.1.3.2 Mexico: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)

10. North America Biopharmaceuticals Market - Industry Landscape

  • 10.1 Overview
  • 10.2 Organic Growth Strategies
    • 10.2.1 Overview
  • 10.3 Inorganic Growth Strategies
    • 10.3.1 Overview

11. Company Profiles

  • 11.1 Amgen Inc
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 AbbVie Inc
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Eli Lilly and Co
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Bristol-Myers Squibb Co
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Johnson & Johnson
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Boehringer Ingelheim International GmbH
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Thermo Fisher Scientific Inc
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 AGC Biologics AS
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Lonza Group AG
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments
  • 11.10 WuXi Biologics Inc
    • 11.10.1 Key Facts
    • 11.10.2 Business Description
    • 11.10.3 Products and Services
    • 11.10.4 Financial Overview
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms

List Of Tables

  • Table 1. North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Table 2. United States Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 3. United States Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
  • Table 4. United States Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
  • Table 5. United States Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
  • Table 6. United States Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
  • Table 7. United States Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
  • Table 8. United States Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
  • Table 9. United States Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
  • Table 10. United States Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
  • Table 11. United States Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • Table 12. Canada Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 13. Canada Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
  • Table 14. Canada Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
  • Table 15. Canada Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
  • Table 16. Canada Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
  • Table 17. Canada Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
  • Table 18. Canada Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
  • Table 19. Canada Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
  • Table 20. Canada Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
  • Table 21. Canada Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • Table 22. Mexico Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
  • Table 23. Mexico Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
  • Table 24. Mexico Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
  • Table 25. Mexico Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
  • Table 26. Mexico Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
  • Table 27. Mexico Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
  • Table 28. Mexico Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
  • Table 29. Mexico Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
  • Table 30. Mexico Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
  • Table 31. Mexico Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
  • Table 32. Recent Organic Growth Strategies in Biopharmaceuticals Market
  • Table 33. Recent Inorganic Growth Strategies in the North America biopharmaceuticals market
  • Table 34. Glossary of Terms

List Of Figures

  • Figure 1. North America Biopharmaceuticals Market Segmentation
  • Figure 2. North America Biopharmaceuticals Market, by Country
  • Figure 3. North America Biopharmaceuticals Market Overview
  • Figure 4. Monoclonal Antibodies Segment Held Largest Share of Product Type Segment in North America Biopharmaceuticals Market
  • Figure 5. US Expected to Show Remarkable Growth During Forecast Period
  • Figure 6. North America: PEST Analysis
  • Figure 7. Experts\' Opinion
  • Figure 8. North America Biopharmaceuticals Market: Impact Analysis of Drivers and Restraints
  • Figure 9. North America Biopharmaceuticals Market - Revenue Forecast and Analysis - 2020-2028
  • Figure 10. North America Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
  • Figure 11. Monoclonal Antibodies: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 12. Recombinant Vaccines: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 13. Cancer Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 14. Malaria Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 15. Ebola Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 16. Hepatitis-B Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 17. Tetanus Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 18. Diphtheria Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 19. Cholera Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 20. Others: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 21. Conventional Vaccines: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 22. Polio Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 23. Pox Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 24. Other Conventional Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 25. Recombinant Growth Factors: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 26. Erythropoietin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 27. Granulocyte Colony Stimulating Factor: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 28. Purified Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 29. Leukemia Inhibitory Factor (LIF): North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 30. P53 Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 31. P38 Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 32. Other Purified Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 33. Recombinant Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 34. Serum Albumin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 35. Amyloid Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 36. Defensin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 37. Transferrin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 38. Recombinant Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 39. Recombinant Human Growth Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 40. Recombinant Insulin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 41. Other Recombinant Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 42. Recombinant Enzymes: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 43. Enterokinase: north America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 44. Cyclase: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 45. Caspase: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 46. Cathepsin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 47. Cell and Gene Therapies: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 48. Allogenic Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 49. Autologous Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 50. Acellular Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 51. Cytokines/Interferon/Interleukins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 52. Others (mRNA Based Therapeutics, etc.): North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 53. North America Biopharmaceuticals Market, by Application 2021 & 2028 (%)
  • Figure 54. Oncology: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 55. Inflammatory and Infectious Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 56. Autoimmune Disorders: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 57. Metabolic Disorders: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 58. Hormonal Disorders and Growth Failure: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 59. Cardiovascular Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 60. Neurological Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 61. Other Therapeutic Applications: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 62. North America: Biopharmaceuticals Market, by Key Country - Revenue (2021) (US$ Million)
  • Figure 63. North America: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
  • Figure 64. United States: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 65. Canada: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • Figure 66. Mexico: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)